Expertise in
12
conditions

Dr. Scott Sonnier

Hematology Oncology
2820 Napoleon Ave, 
New Orleans, LA 
On Staff At
Accepting New Patients
Offers Telehealth
Expertise in
12
conditions
2820 Napoleon Ave, 
New Orleans, LA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Scott Sonnier is a Hematologist Oncology provider in New Orleans, Louisiana. Dr. Sonnier is highly rated in 12 conditions, according to our data. His top areas of expertise are Paget Disease of the Breast, Intraductal Papilloma, Pleuropulmonary Blastoma, Lung Cancer, and Bone Marrow Aspiration. Dr. Sonnier is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Licenses
Internal Medicine in LA
Board Certifications
American Board Of Internal Medicine - Hematology/Oncology
Hospital Affiliations
St Bernard Parish Hospital
Ochsner Medical Center Acute
Touro Infirmary
Ochsner Medical Center-Kenner
Ochsner Medical Center - Baton Rouge
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Louisiana Healthcare Connections
  • HMO
  • MANAGED MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Primewell Health Services
  • HMO
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE PART D
  • POS
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Ochsner Health Center - Baptist Napoleon Medical Plaza
2820 Napoleon Ave, New Orleans, LA 70115
Other Locations
The Gayle and Tom Benson Cancer Center
1514 Jefferson Highway, New Orleans, LA 70121
Ochsner Medical Complex - The Grove
10310 The Grove Blvd, Baton Rouge, LA 70836
Ochsner Cancer Center - Baton Rouge
17050 Medical Center Drive, Baton Rouge, LA 70816

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Enrollment Status: Completed
Publish Date: March 17, 2025
Intervention Type: Drug, Biological
Study Drugs: Margetuximab, Trastuzumab, Capecitabine, Eribulin, Gemcitabine, Vinorelbine
Study Phase: Phase 3
A Randomized Phase III Trial of OSE2101 Compared With Chemotherapy (Docetaxel or Pemetrexed) in HLA-A2 Positive Patients With Advanced Non-Small Cell Lung Cancer With Progressive Disease After Immune Checkpoint Inhibitors
A Randomized Phase III Trial of OSE2101 Compared With Chemotherapy (Docetaxel or Pemetrexed) in HLA-A2 Positive Patients With Advanced Non-Small Cell Lung Cancer With Progressive Disease After Immune Checkpoint Inhibitors
Enrollment Status: Terminated
Publish Date: February 02, 2024
Intervention Type: Drug, Biological
Study Drugs: OSE2101, Docetaxel, Pemetrexed
Study Phase: Phase 3
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Enrollment Status: Completed
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drugs: Ribociclib, Letrozole, Goserelin, Leuprolide
Study Phase: Phase 3
P2 Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- MBC in Patients Who Have Shown Previous Disease Progression on a Nonsteroidal Aromatase Inhibitor, Fulvestrant and CDK 4/6 Inhibitor
P2 Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- MBC in Patients Who Have Shown Previous Disease Progression on a Nonsteroidal Aromatase Inhibitor, Fulvestrant and CDK 4/6 Inhibitor
Enrollment Status: Withdrawn
Publish Date: March 24, 2023
Intervention Type: Drug
Study Drugs: Sabizabulin, Exemestane, Everolimus, Selective estrogen receptor modulator
Study Phase: Phase 2
View 3 Less Clinical Trials

1 Total Publications

Multidimensional biomarker predicts disease control in response to immunotherapy in recurrent or metastatic head and neck squamous-cell carcinoma.
Multidimensional biomarker predicts disease control in response to immunotherapy in recurrent or metastatic head and neck squamous-cell carcinoma.
Journal: Journal of cancer research and clinical oncology
Published: June 26, 2023
Similar Doctors
Expertise in
25
conditions
Dr. Laura E. Finn
Hematology Oncology
Expertise in
25
conditions
Dr. Laura E. Finn
Hematology Oncology

The Gayle And Tom Benson Cancer Center

1514 Jefferson Highway, 
New Orleans, LA 
 (60.8 miles away)
504-842-3910
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Laura Finn is a Hematologist Oncology provider in New Orleans, Louisiana. Dr. Finn is highly rated in 25 conditions, according to our data. Her top areas of expertise are Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma, Acute Myeloblastic Leukemia without Maturation, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Finn is currently accepting new patients.

Expertise in
10
conditions
Dr. John T. Cole
Hematology Oncology | Hematology | Oncology
Expertise in
10
conditions
Dr. John T. Cole
Hematology Oncology | Hematology | Oncology

Ochsner Clinic LLC

1514 Jefferson Hwy, 
New Orleans, LA 
 (60.8 miles away)
504-842-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

John Cole is a Hematologist Oncology specialist and a Hematologist in New Orleans, Louisiana. Dr. Cole is highly rated in 10 conditions, according to our data. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, Bone Marrow Aspiration, and Endoscopy. Dr. Cole is currently accepting new patients.

Expertise in
13
conditions
Dr. Chris G. Theodossiou
Hematology Oncology
Expertise in
13
conditions
Dr. Chris G. Theodossiou
Hematology Oncology

Ochsner Medical Center - New Orleans

1514 Jefferson Highway, 
New Orleans, LA 
 (60.8 miles away)
504-842-3910
Languages Spoken:
English, French, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Chris Theodossiou is a Hematologist Oncology provider in New Orleans, Louisiana. Dr. Theodossiou is highly rated in 13 conditions, according to our data. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, Bone Marrow Aspiration, and Endoscopy. Dr. Theodossiou is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sonnier's expertise for a condition
ConditionClose
    View All 11 Advanced Conditions
    View All 102 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile